Fundies.
English

Segment disclosures

Company overview

SWK Holdings Corporation

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

3 dimension combinations 43 retained observations 10 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Pharmaceutical Development · Pharmaceutical Development Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=swkh:PharmaceuticalDevelopmentMember;us-gaap:StatementBusinessSegmentsAxis=swkh:PharmaceuticalDevelopmentSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-312153000 USD20260320Open filing evidence
2025-07-01 – 2025-09-300 USD20251106Open filing evidence
2025-01-01 – 2025-09-302153000 USD20251106Open filing evidence
2025-04-01 – 2025-06-301190000 USD20250814Open filing evidence
2025-01-01 – 2025-06-302153000 USD20250814Open filing evidence
2025-01-01 – 2025-03-31963000 USD20250515Open filing evidence
2024-01-01 – 2024-12-313567000 USD20260320Open filing evidence
2024-07-01 – 2024-09-30628000 USD20251106Open filing evidence
2024-01-01 – 2024-09-301662000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30755000 USD20250814Open filing evidence
2024-01-01 – 2024-06-301034000 USD20250814Open filing evidence
2024-01-01 – 2024-03-31279000 USD20250515Open filing evidence
2023-01-01 – 2023-12-31931000 USD20250320Open filing evidence
2023-07-01 – 2023-09-30315000 USD20241114Open filing evidence
2023-01-01 – 2023-09-30606000 USD20241114Open filing evidence

License And Service · Pharmaceutical Development Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:LicenseAndServiceMember;us-gaap:StatementBusinessSegmentsAxis=swkh:PharmaceuticalDevelopmentSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260320Open filing evidence
2025-07-01 – 2025-09-300 USD20251106Open filing evidence
2025-01-01 – 2025-09-300 USD20251106Open filing evidence
2025-04-01 – 2025-06-300 USD20250814Open filing evidence
2025-01-01 – 2025-06-300 USD20250814Open filing evidence
2024-01-01 – 2024-12-3149000 USD20260320Open filing evidence
2024-07-01 – 2024-09-300 USD20251106Open filing evidence
2024-01-01 – 2024-09-3049000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3049000 USD20250814Open filing evidence
2024-01-01 – 2024-06-3049000 USD20250814Open filing evidence
2023-01-01 – 2023-12-31273000 USD20250320Open filing evidence
2023-07-01 – 2023-09-300 USD20241114Open filing evidence
2023-01-01 – 2023-09-3010000 USD20241114Open filing evidence

Pharmaceutical Development Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=swkh:PharmaceuticalDevelopmentSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-312153000 USD20260320Open filing evidence
2025-07-01 – 2025-09-300 USD20251106Open filing evidence
2025-01-01 – 2025-09-302153000 USD20251106Open filing evidence
2025-04-01 – 2025-06-301190000 USD20250814Open filing evidence
2025-01-01 – 2025-06-302153000 USD20250814Open filing evidence
2025-01-01 – 2025-03-31963000 USD20250515Open filing evidence
2024-01-01 – 2024-12-313616000 USD20260320Open filing evidence
2024-07-01 – 2024-09-30628000 USD20251106Open filing evidence
2024-01-01 – 2024-09-301711000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30804000 USD20250814Open filing evidence
2024-01-01 – 2024-06-301083000 USD20250814Open filing evidence
2024-01-01 – 2024-03-31279000 USD20250515Open filing evidence
2023-01-01 – 2023-12-311204000 USD20250320Open filing evidence
2023-07-01 – 2023-09-30315000 USD20241114Open filing evidence
2023-01-01 – 2023-09-30616000 USD20241114Open filing evidence